2 results
Approved WMOPending
Main objective: To evaluate the efficacy of BIIB122 225 mg compared with placebo.Secondary objective: To evaluate the efficacy, safety and tolerability of BIIB122 225 mg compared with placebo in participants with early-stage PDObjective optional (…
Approved WMORecruiting
To investigate the effect the effect of a 3-months treatment with Reslizumab on small airways function in patients with severe eosinophilic asthma, and to relate the changes in small airway function to changes in asthma symptoms and quality of life.